Last reviewed · How we verify
neuromuscular blockade group
At a glance
| Generic name | neuromuscular blockade group |
|---|---|
| Also known as | rocuronio |
| Sponsor | Nantes University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Procedural pain
- Constipation
- Nausea
- Pain
- Sleep disorder
- Anaemia
- Vomiting
- Anaemia postoperative
- Haematoma
- Arthralgia
- Oedema peripheral
- Insomnia
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry (NA)
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Mind Body Balance for Pediatric Migraine (NA)
- Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |